DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Omaxe Limited — Product launch (Sub-para 3-Para B)

NSE 1 hr ago·17 Oct 2026, 6:58 am

Omaxe

Omaxe Limited has informed the stock exchanges about the launch of a new product line. This announcement signals the company's continued efforts to expand its business portfolio and diversify its revenue streams.

For investors, this development is a positive indicator of management's strategic focus on growth. It suggests Omaxe is actively working to strengthen its market position and explore new avenues for business development.

Investors should watch for details on the product's market reception and its potential to contribute to the company's overall financial performance in the coming quarters.